Using myeloma and osteosarcoma cell lines as targets, we demonstrated here that the treatment of ex vivo-expanded Vγ9Vδ2 T cells with IL-12 and IL-18 enhanced their cytotoxic activity against tumor cell lines. The gene discussed is IL18; the disease is plasma cell myeloma.